Abstract
Background: Nimodipine is the most widely preferred and administered calcium channel blocker in cerebral vasospasm prevention and treatment. There is no experimental or clinical study investigating the comparative effects of routine treatment modalities.
Method: 35 male New Zealand White rabbits were assigned randomly to one of seven groups: Control, only SAH, SAH/oral nimodipine, SAH/IV nimodipine, SAH/IT nimodipine, SAH/IA nimodipine, SAH/angiography.
Findings: Basilar artery vessel diameters are measured by angiography. Basilar artery vessel diameters and luminal sectional areas are measured in pathology slides. Basilar artery thicknesses were significantly higher in group 2 and 7 than the others (p < 0.05). Luminal sectional areas in group 5 and 6 were significantly higher than other groups (p < 0.05). We found no significant difference in group 1, 5 and 6 (p > 0.05). Basilar section areas in group 3 and 4 were significantly higher than group 2 but lower than group 1.
Conclusion: This is the first study to show the most effective drug delivery route in CVS after SAH. Nimodipine treatment in cerebral vasospasm is useful. This study showed that selective IA nimodipine treatment and IT nimodipine treatment must be preferred to IV and oral treatments of chronic vasospasm following SAH.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Böker DK, Solymosi L, Wassmann H. Immediate postangiographic intraarterial treatment of cerebral vasospasm after subarachnoid hemorrhage with nimodipine. Report on 3 cases. Neurochirurgia (Stuttg) 1985;28 Suppl 1:118–20.
Conti A, Angileri FF, Longo M, Pitrone A, Granata F, La Rosa G. Intra-arterial nimodipine to treat symptomatic cerebral vasospasm following traumatic subarachnoid haemorrhage. Technical case report. Acta Neurochir (Wien). 2008;150(11):1197–202.
Firat MM, Gelebek V, Orer HS, Belen D, Firat AK, Balkanci F. Selective intraarterial nimodipine treatment in an experimental subarachnoid hemorrhage model. Am J Neuroradiol. 2005;26(6):1357–62.
Gioia AE, White RP, Bakhtian B, Robertson JT Evaluation of the efficacy of intrathecal nimodipine in canine models of chronic cerebral vasospasm. J Neurosurg. 1985;62(5):721–8.
Grotenhuis JA, Bettag W, Fiebach BJ, Dabir K. Intracarotid slow bolus injection of nimodipine during angiography for treatment of cerebral vasospasm after SAH. A preliminary report. J Neurosurg. 1984;61(2):231–40.
Ishida T, Takanashi Y, Kiwada H. Safe and efficient drug delivery system with liposomes for Intrathecal application of an antivasospastic drug, fasudil. Biol Pharm Bull. 2006;29(3):397–402.
Laslo AM, Eastwood JD, Chen FX, Lee TY. Dynamic CT perfusion imaging in subarachnoid hemorrhage-related vasospasm. Am J Neuroradiol. 2006;27(3):624–31.
Marbacher S, Neuschmelting V, Graupner T, Jakob SM, Fandino J. Prevention of delayed cerebral vasospasm by continuous intrathecal infusion of glyceroltrinitrate and nimodipine in the rabbit model in vivo. Intensive Care Med. 2008;34(5):932–8.
Mayer ET, Dichgans M, Straube A, Birnmaum T. Continuous intraarterial nimodipine for the treatment of cerebral vasospasm. Cardiovasc Intervent Radiol. 2008;31:1200–4.
Mercier P, Alhayek G, Rizk T, Fournier D, Menei P, Guy G. Are the calcium antagonists really useful in cerebral aneurysmal surgery? A retrospective study. Neurosurgery 1994;34(1):30–6.
Pickard JD, Murray GD, Illingworth R, Shaw MD, Teasdale GM, Foy PM, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ. 1989;298(6674):636–42.
Rinkel GJ, Feigin VL, Algra A, van den Bergh WM, Vermeulen M, van Gijn J. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2005;25(1):CD000277.
Strong MJ, Garruto RM, Wolff AV, Chou SM, Fox SD, Yanagiharoi R. N-butyl benzenesulfonamide: a neurotoxic plasticizer inducing a spastic myelopathy in rabbits. Acta Neuropathol (Berl). 1991;81:235–41.
Strong MJ, Wolff AV, Wakayama I, Garruto RM. Aluminum-induced chronic myelopathy in rabbits. Neurotoxicology 1991;12:9–21.
Toyota BD. The efficacy of an abbreviated course of nimodipine in patients with good-grade aneurysmal subarachnoid hemorrhage. J Neurosurg. 1999;90(2):203–6.
Vatter H, Weidauer S, Konczalla J, Dettmann E, Zimmermann M, Raabe A, et al. Time course in the development of cerebral vasospasm after experimental subarachnoid hemorrhage: clinical and neuroradiological assessment of the rat double hemorrhage model. Neurosurgery 2006;58(6):1190–7.
Vinge E, Andersson KE, Brandt L, Ljunggren B, Nilsson LG, Rosendal-Helgesen S. Pharmacokinetics of nimodipine in patients with aneurysmal subarachnoid haemorrhage. Eur J Clin Pharmacol. 1986;30(4):421–5.
Xiong R, Lu W, Li J, Wang P, Xu R, Chen T. Preparation and characterization of intravenously injectable Nimodipine nanosuspension. Int J Pharm. 2008;350(1–2):338–43.
Zabramski J, Spetzler RF, Bonstelle C. Chronic cerebral vasospasm: effect of calcium antagonists. Neurosurgery 1986;18(2):129–35.
Acknowledgement
Turkish Neurosurgery Society founded this study.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag/Wien
About this paper
Cite this paper
Onal, M.B. et al. (2011). Comparison of Nimodipine Delivery Routes in Cerebral Vasospasm After Subarachnoid Hemorrhage: An Experimental Study in Rabbits. In: Feng, H., Mao, Y., Zhang, J.H. (eds) Early Brain Injury or Cerebral Vasospasm. Acta Neurochirurgica Supplements, vol 110/2. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0356-2_5
Download citation
DOI: https://doi.org/10.1007/978-3-7091-0356-2_5
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-0355-5
Online ISBN: 978-3-7091-0356-2
eBook Packages: MedicineMedicine (R0)